Susan Molineaux

Title: Susan Molineaux: Innovator in Amyloid Research

Introduction

Susan Molineaux is a prominent inventor based in Brookline, MA (US). She has made significant contributions to the field of amyloid research, particularly in the development of compounds that modulate β-amyloid peptide aggregation. With a total of 6 patents to her name, Molineaux's work has the potential to impact the treatment of amyloidogenic diseases.

Latest Patents

Molineaux's latest patents focus on modulators of β-amyloid peptide aggregation comprising D-amino acids. These compounds are designed to modulate natural β-amyloid peptide aggregation and include peptides that are entirely composed of D-amino acids. The preferred peptides consist of 3-5 D-amino acid residues, with at least two residues selected from D-leucine, D-phenylalanine, and D-valine. A particularly notable embodiment is a retro-inverso isomer of a β-amyloid peptide, specifically a retro-inverso isomer of Aβ. The peptides may also be modified at the amino-terminus, carboxy-terminus, or both, with various preferred modifying groups. Additionally, pharmaceutical compositions and diagnostic methods for amyloidogenic diseases utilizing these compounds are disclosed.

Career Highlights

Molineaux is currently associated with Praecis Pharmaceuticals, Inc., where she continues her innovative work in the field. Her research has garnered attention for its potential applications in treating diseases related to amyloid aggregation.

Collaborations

Some of her notable coworkers include Mark A Findeis and Malcolm L Gefter, who have collaborated with her on various projects within the realm of amyloid research.

Conclusion

Susan Molineaux's contributions to the field of amyloid research through her innovative patents and collaborations highlight her role as a leading inventor in this critical area of study. Her work continues to pave the way for advancements in the treatment of amyloidogenic diseases.